Overview
Biotech
Developing synthetic psilocybin (SYNP-101) for OCD and smoking cessation, plus non-hallucinogenic LSD derivative BOL-148. Research partnerships with Yale, NYU, and Harvard.
Visit Website0
Open Roles
Open Positions
No open positions at this time
Clinical Pipeline
No clinical trials on record